Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.73 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12082508 | 0.83 | HRH3 (0.76) | HRH3HRH4LMNAALDH1A1GBA1 | |
| SCHEMBL26351789 | 0.82 | HRH3 (0.69) | HRH3HRH4LMNAACHECHEK1 | |
| SCHEMBL25728926 | 0.82 | HRH3 (0.69) | HRH3HRH4LMNAALDH1A1ACHE | |
| SCHEMBL1889867 | 0.81 | HRH3 (0.73) | HRH3HRH4ALDH1A1ACHESMN1; SMN2 | |
| SCHEMBL1427959 | 0.81 | HRH3 (0.73) | HRH3HRH4ALDH1A1ACHESMN1; SMN2 | |
| SCHEMBL1896032 | 0.81 | HRH3 (0.73) | HRH3HRH4ALDH1A1ACHESMN1; SMN2 | |
| SCHEMBL1427573 | 0.81 | HRH3 (0.73) | HRH3HRH4ALDH1A1ACHESMN1; SMN2 | |
| SCHEMBL4094335 | 0.81 | HRH3 (0.72) | HRH3HRH4LMNAGBA1ACHE | |
| SCHEMBL4094330 | 0.81 | HRH3 (0.72) | HRH3HRH4LMNAGBA1ACHE | |
| SCHEMBL4094332 | 0.81 | HRH3 (0.72) | HRH3HRH4LMNAGBA1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224170-B9 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2017-11-22 | — | — | EP | disclosed |
| CN-101277689-B | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA NV | 2011-01-12 | — | — | CN | disclosed |
| EP-2157081-A1 | Indolinones substituted in six locations, their manufacture and their application as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| EP-1224170-B1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| CN-100455568-C | 6-position substituted indoline, production and use thereof as medicament | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-01-28 | — | — | CN | disclosed |
| CN-101277689-A | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-01 | — | — | CN | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-20050245500-A1 | Beta-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | disclosed |
| US-6545035-B1 | Having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-08 | — | — | US | disclosed |
| CN-1391557-A | 6-substituted indolinones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-01-15 | — | — | CN | disclosed |
| US-6319918-B1 | FOR LYMPHOMA OR SOLID TUMORS TREATMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-11-20 | — | — | US | disclosed |
| CN-1303374-A | Substituted indolinones, process for their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-07-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | HRH3 869/4885HRH4 990/4885LMNA 1884/4885 |
| US-20050245500-A1 | Beta-ketoamide compounds with MCH antagonistic activity | MCHR2, MCHR1, NPY1R | HRH3 86/4885HRH4 57/4885LMNA 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.